Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
video icon
Bioprocessing Expert Panel Discussion Part 2 – PAT Strategies
external link icon
Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters’ Option
WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 million shares of its common stock at a public offering price of $181 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $312.2 million, which includes the exercise in full of the underwriters’ option to purchase 225,000 additional shares. The offering of the shares is expected to result in approximately $298 million in net proceeds to Repligen after deducting underwriting discounts and commissions and other estimated offering expenses payable by Repligen. Repligen Corporation intends to use the net proceeds from this offering for working capital and other general corporate purposes. Net proceeds from this offering may also be used to fund possible acquisitions of, or investments in, complementary businesses,
external link icon
Repligen Announces Conference Call to Discuss Phase 3 Clinical Results of RG1068 in MRI Imaging of the Pancreas Wednesday, December 9th, 8:30 a.m. EST
external link icon
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington’s Disease Model
news icon
Repligen strengthens downstream offering with $200m ARTeSYN acquisition
news icon
Repligen adds single-use filtration technology through TangenX acquisition
video icon
Bioprocessing Expert Panel Discussion Part 1 – PAT Implementation
external link icon
Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options
WALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the closing of its previously announced concurrent underwritten public offerings of an aggregate of 1,587,000 shares of its common stock (the “Shares”) at a public offering price of $87.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $138.1 million, and $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”), which includes the exercise in full of the underwriters’ option to purchase 207,000 additional Shares and $37.5 million additional Notes. The offering of the Shares (the “Shares Offering”) is expected to result in approximately $130.7 million in net proceeds to Repligen after deducting underwriting discounts and commissions and other estimated offering expenses payable by Repligen. The offering of the Notes (the “Notes Offering” and,
external link icon
Repligen Receives Additional Research Grants to Support Development of HDAC Inhibitors for Friedreich’s Ataxia and Huntington’s Disease
video icon
Evaluating the new CTech FlowVPX System for UF/DF-Protein Concentration (Bristol-Myers Squibb)
An evaluation of a beta version of the FlowVPX and Viper software was performed to determine it’s potential as an inline instrument for product concentration measurement during UF/DF operation, particularly high concentration UF/DF processes that are required for subcutaneous injection formulations (greater than 150 g/L). The FlowVPX has significant potential for GMP and commercial biologics manufacturing unlike the first generation FlowVPE, which was designed as a lab scale instrument. Extensive testing was done using small and pilot scale UF/DF operations with several biologic drugs molecules from the portfolio. The FlowVPX instrument demonstrated very good comparability with other A280 based protein concentration measurements for all molecules tested (six). From a technical standpoint the FlowVPX is a GMP ready instrument, and further testing for instrument robustness and software development is ongoing at present to potentially use the instrument in the GMP space within the near future. Speaker: Jay West, Ph.D., Principal Scientist Biologics Process Development – BMS.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support